news
Pfizer receives CHMP negative opinion regarding marketing authorization in Europe for Rheumatoid Arthritis treatment XELJANZ® (tofacitinib citrate)
25 April 2013 | By Pfizer
Pfizer intends to appeal and seek re-examination...
List view / Grid view
Pfizer
news
Palbociclib receives FDA Breakthrough Therapy designation for potential treatment of patients with breast cancer
10 April 2013 | By Pfizer
Palbociclib has received Breakthrough Therapy designation...
news
CHOP collaborates with Pfizer’s Centers for Therapeutic Innovation to speed pediatric research & development
3 April 2013 | By Pfizer
CHOP and Pfizer are joining forces...
news
Pfizer’s BOSULIF® (bosutinib) receives conditional marketing authorization from the European Commission
28 March 2013 | By Pfizer
“I’m delighted the EC has approved BOSULIF..."
news
XELJANZ® approved in Japan for the treatment of adults with rheumatoid arthritis
25 March 2013 | By Pfizer
“RA is a serious and disabling disease and there is a need for new treatment options..."
news
New trial results support treatment with Inspra within first 24 hours of symptoms in patients with acute STEMI without heart failure
10 March 2013 | By Pfizer
Results from the REMINDER trial...
news
Pfizer presents Phase 3 safety and immunogenicity data on Prevnar 13® in adults with HIV
4 March 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
webinar
Leveraging cutting-edge Rapid Microbiological Methods to gain a comprehensive understanding of your environment and a competitive advantage
5 February 2013 | By Abzil BioVigilant
This webinar offers insight from both an end user and a supplier in order to share with you compelling reasons to consider the use of RMMs to gain a better understanding of your environment while improving your competitive advantage...
news
Pfizer receives FDA approval for the use of Prevnar 13
25 January 2013 | By Pfizer
Prevnar 13 is the first and only pneumococcal conjugate vaccine approved for this age group...
news
Pfizer announces top-line efficacy results from a Phase 4 study of PRISTIQ® (desvenlafaxine)
24 January 2013 | By Pfizer
New data add to evidence supporting PRISTIQ as a treatment option for MDD...
news
Pfizer partnership organizations significantly benefit from Pfizer’s Global Health Fellows Program
22 January 2013 | By Pfizer
Pfizer celebrates 10th anniversary of this signature social investment program...
news
Pfizer’s Bosutinib receives positive opinion
18 January 2013 | By Pfizer
“We are very pleased with this positive recommendation on bosutinib by the CHMP..."
news
Pfizer announces availability of Quillivant XR™ CII for extended-release oral suspension in the United States
14 January 2013 | By Pfizer
Quillivant XR™ CII for extended-release oral suspension is now available...
news
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
3 January 2013 | By EMD Serono; Pfizer Inc.
The majority of patients found Rebif Rebidose easy to use in a user trial...
news
U.S. FDA Approves ELIQUIS® (apixaban)
2 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...
